Age, years
|
RA
SpA
CD
|
55.5
42.85
41.17
|
51.64
42.9
38.42
|
NS
NS
NS
|
Sex ratio
|
RA
SpA
CD
|
0.2
3.3
1
|
0.3
5.6
1.3
|
NS
NS
NS
|
BMI, kg/m2 (mean ± SD)
|
RA
SpA
CD
|
33 ± 1.2
22 ± 0.8
21.8 ± 0.3
|
26.5 ± 1.7
19.71 ± 0.9
20.58 ± 1.3
|
0.04
NS
NS
|
Mean age at disease onset, years (mean ± SD)
|
RA
SpA
CD
|
39.33 ± 3.5
31.23 ± 2.8
30.83 ± 1.9
|
36.82 ± 2.8
33.25 ± 0.6
28 ± 3.1
|
NS
NS
NS
|
Disease duration, years
(mean ± SD)
|
RA
SpA
CD
|
9.08 ± 3.2
7.3 ± 2.1
17.17 ± 4.2
|
3.05 ± 1.1
6.3 ± 1.9
23.14 ± 4.8
|
NS
NS
NS
|
Duration of TNF alpha blockers therapy, months (mean ± SD)
|
RA
SpA
CD
|
51.83 ± 7.9
26.46 ± 6.9
5.17 ± 1.1
|
32.36 ± 11.2
39.9 ± 9.9
4.4 ± 1.3
|
NS
NS
NS
|
Concomitant use of MTX, n
|
RA
SpA
CD
|
9
5
0
|
12
6
3
|
NS
NS
0.04
|
Mean dose of MTX, mg/week
|
RA
SpA
CD
|
10 ± 2.5
15 ± 2.3
|
13.5 ± 2.8
16.5 ± 2.9
20
|
0.04
NS
0.005
|
Concomitant use of AZA, n
|
RA
SpA
CD
|
0
0
12
|
0
0
21
|
-
-
NS
|
Mean dose of AZA, mg/kg/day
|
RA
SpA
CD
|
0
0
2,5 ± 0.9
|
0
0
2 ± 0.2
|
-
-
NS
|